OXFORD, England, February 11th 2015.

PharmaVentures is pleased to announce that it is to increase its life science presence in North America by establishing a new base in Boston, MA. Starting this month Dr Adrian Dawkes, VP, will be dividing his time between the USA and the UK.

This announcement follows a record year for mandates in M&A and licensing for PharmaVentures.

Dr. Fintan Walton, CEO, PharmaVentures, commented: “With America still the biggest market for healthcare and with Boston leading life science innovation it makes immense sense for us to have one of our most experienced deal makers on the ground. Increasingly our clients need access to the opportunities that America offers and Adrian’s contacts and experience will be of great value to them.”   

Dr Adrian Dawkes, VP, added “With a growing number of pharma clients and deals in America, including those involving major pharmaceutical companies such as Pfizer and Merck and leading life science companies, we would like to provide support and interact directly with leading innovators and healthcare companies in The USA as well as worldwide.”  

Should you wish to meet up with Adrian to discuss your needs and our capabilities please drop him an email or give him a call on +44 7931 428487.

adrian@pharmaventures.com

– Ends-

OXFORD, UK, January 27th, 2015.

PharmaVentures is pleased to announce that their client Novartis has entered into exclusive negotiations with the University of Brighton on the purchase of its UK Horsham site announced on the 26th January 2015.

The University of Brighton plans to open an innovative, high-quality centre for higher education in Horsham that will give a major boost to jobs, skills and business opportunities in the Gatwick Diamond area. The university estimates the centre could create an estimated 2,250 new jobs and bring £1.7bn of investment to the region over 10 years, and provide around 3,500 places forstudents.

PharmaVentures was appointed by Novartis as exclusive advisors on the sale of its Horsham site based in the UK in April 2014.

Fintan Walton, Chief Executive, PharmaVentures, Ltd said: “We are delighted that our client Novartis has entered into exclusive negotiations on the potential sale of the Horsham site to University of Brighton. This would have a huge positive impact on the region and provides a positive legacy for Novartis too “.

Nigel Borshell, Vice President, who led the advisory team at PharmaVentures added:“This potential sale will be an important land mark deal with respect to the future use of former manufacturing and R&D sites.”

For the past 23 years, PharmaVentures has acted as advisor to over 700 global pharmaceutical and biotechnology clients in transactions; covering licensing, pharma mergers, acquisitions, divestments and joint venture activities for companies.

Pharma licensing agreement OXFORD, UK, January 13th, 2015

PharmaVentures is pleased to announce that it has acted as advisor to ESTEVE in their successful license agreement with MundiPharma Laboratories GmbH for E-58425, a first in class NSAID/Opioid API-API co-crystal for the treatment of pain.

ESTEVE is a privately-held pharmaceutical and chemical group that focuses on innovation and excellence in health.  In a Phase II clinical study in post-operative pain, E-58425 demonstrated significant superior efficacy and safety compared to a standard of care.

Adrian Dawkes, Vice President, PharmaVentures Ltd. who was lead advisor to ESTEVE commented: “We are delighted to have worked with ESTEVE in partnering E-58425 which represents a great step forward in the pain sector.”

Fintan Walton, Chief Executive, PharmaVentures, Ltd added: “We continue to be recognised as a strong leader in healthcare deal making and this adds to a growing list of our recent successes”.

For the past 23 years, PharmaVentures has acted as advisor to over 600 global pharmaceutical and biotechnology clients in transactions; covering licensing, mergers, acquisitions, divestments and joint venture activities for companies.

Oxford, UK, January 12th 2015

PharmaVentures has become the latest Partner to join forces with One Nucleus. Both PharmaVentures and One Nucleus are committed to playing an active and supportive role in assisting in the success of the life sciences sector nationally and internationally. 

The One Nucleus mission is to help enable its member companies to be globally competitive. A key element of supporting their members in achieving such competitiveness is enabling access to first class commercial intelligence and corporate advisory services. Such support provides businesses with the best possible opportunity to develop timely and effective strategies for success. PharmaVentures, together with their PharmaTelevision business, will make their services at specially reduced rates to One Nucleus members.

Fintan Walton, CEO of PharmaVentures explained, “We are delighted to be working with One Nucleus in support of their membership. The support we can make available through our corporate advisory services and PharmaTelevision will make the difference to their partnering and development strategies”.

Harriet Fear, CEO of One Nucleus said, “Our Partner Programme is a bespoke package of support and collaboration between One Nucleus and larger organisations who are central to the success of the sector. We are very excited that PharmaVentures has become a One Nucleus Partner and is involved in a range of our activities including ON Helix – our major Cambridge based translational research conference we host annually, our Life Science Leadership Series and the Ask One Nucleus online Dashboard”.

About One Nucleus

One Nucleus is an international membership organisation for life science and healthcare companies. We are based in Cambridge with the majority of our members across the Cambridge/London corridor – at the heart of Europe’s largest life science and healthcare cluster.

Organisation History

Established in 1997, One Nucleus is a not-for-profit membership organisation located in Cambridge. We have over 470 organisations as members, including pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial service providers.

One Nucleus’ mission is to maximise the global competitiveness of our members.  For our science and technology-based members, that means them being global leaders in the research, development and commercialisation of healthcare innovations that radically improve the quality of people’s lives around the world. For our business and professional services members, it means them delivering exceptional services that significantly enhance the business performance of their clients.

For further information, contact:

Tony Jones, Director of Business Development

Email: tony@onenucleus.com

Tel: +44 (0)1223 896450

Web:  www.onenucleus.com

OXFORD, UK, October 1st, 2014

PharmaVentures is pleased to announce that it has acted as advisor on deal terms to Plethora Solutions Holdings on their recently signed Licensing Agreement with Recordati to commercialise PSD502™, a novel treatment for premature ejaculation.

Under the terms of the agreement Plethora are expected to receive upfront and milestone payments of up to €46 million plus royalties.

Stephen Waterman, Vice President, who led the PharmaVentures team on the deal commented: “We are delighted to have worked with Plethora on the deal terms of this important licensing agreement”.

Fintan Walton, Chief Executive, PharmaVentures, Ltd added: “We would like to congratulate Plethora on their licensing agreement with Recordati”.

  – ends –

OXFORD, UK, September 24^th, 2014

PharmaVentures are delighted to announce that Aki von Roy has joined as an Associate, based in Auckland, New Zealand. He has over 30 years experience in Big Pharma and 16 years in biotech. Aki has been involved in over 18 start-up or merger ventures as director or investor.

His experience includes being Founder CEO of Proacta and CoDa Therapeutics and Founding Director of Corra Life Sciences (USA), Biomatters (NZ) and White Biotech (AUS). He is a former chairman of both private and publicly traded companies including Genesis R&D (NZ), Phylogica (AUS), Vital Foods (NZ) and Phytomedics (USA).

Aki von Roy is currently a Venture Partner at BioPacificVentures and an advisor to Direct Capital. He was previously a partner of Inventages (US$1.5 billion life science fund).

Dr Fintan Walton, CEO PharmaVentures, said “Aki has a unique insight into innovative healthcare in the Asia-Pacific region and he will be a great benefit to both PharmaVentures and its clients”.

Aki von Roy added “I am delighted to join PharmaVentures, a firm with a proven track record in deal making”.

Aki is the former European president of Bristol-Myers Squibb, where he was responsible for US$2.2 billion in sales, more than 7,500 employees and some 40 subsidiaries. In 1997, he retired from BMS to establish RvR Associates, a private investment firm specialising in health and related matters.

– ends –